← Back to all trials
Not Yet Recruiting
NCT05610956
Evaluate the Possible Efficacy and Safety of Empagliflozin in Patient With Ulcerative Colitis
Conditions: Ulcerative Colitis
Sex: All
Ages: 18 Years – 70 Years
Phase: EARLY_PHASE1
Enrollment: 60
Sponsor: Tanta University
Summary
•This study will be a randomized, controlled, parallel study.
.To demonstrate the efficacy of empagliflozin and clinical improvement in patients of mild to moderate UC using the Montreal classification of severity of ulcerative colitis.
Eligibility Criteria
Inclusion Criteria:•Patients with mild to moderate UC are diagnosed by history, clinical signs according to the Montreal classification of severity of ulcerative colitis and( Endoscopy, and biopsy) to establish the chronicity of inflammation and to exclude other causes of colitis.Exclusion Criteria:Other inflammatory bowel diseases (CD).History of serious hypersensitivity to empagliflozin or any component of the formulation.Patients on dialysis.Severe renal impairment (eGFR <20 ml/minute/1.73m2) .Chronic urinary tract infection.Chronic genital infection.
Source: ClinicalTrials.gov (NCT05610956). StuddyBuddy aggregates publicly available trial information.